# Non-invasive neurostimulation techniques for the treatment of stimulant use disorders

**Authors:** Jordan Hendy, Hannah Bereznicki, Robert M. Lundin

PMC · DOI: 10.3389/fpsyt.2026.1755441 · Frontiers in Psychiatry · 2026-02-04

## TL;DR

This review evaluates non-invasive brain stimulation techniques for treating stimulant addiction, finding some promise but highlighting the need for better research.

## Contribution

A comprehensive narrative review of non-invasive neurostimulation for stimulant use disorders, identifying research gaps and clinical potential.

## Key findings

- Non-invasive neurostimulation shows variable improvement in cravings, cognition, and affective outcomes for stimulant users.
- Craving is the most commonly assessed outcome in studies on neurostimulation for stimulant use disorders.
- Research limitations include small samples, short follow-up, and inconsistent protocols.

## Abstract

Addictive disorders remain important contributors to the overall burden of disease, and although many have established treatments, stimulant use disorders (StUDs) still lack effective management options. Neurostimulation techniques, such as Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, have attracted addiction medicine researchers and clinicians, with many studies showing promise in reducing cravings and improving other clinical outcomes in participants, as well as modulating relevant brain areas. As a result, research output in this area is increasing rapidly. This narrative review aims to assess currently available research data on non-invasive neurostimulation techniques in patients with StUDs to inform future research requirements and clinical applications. This review was conducted using a comprehensive search strategy across PubMed, OVID Medline and PsycINFO databases, using terms including “stimulant use disorder*”, “transcranial magnetic stimulation” and “craving*”. The initial search was intentionally broad to effectively assess the breadth of literature on neurostimulation in addiction disorders generally, resulting in the return of 1317 sources. Search results were uploaded to Covidence and screened for inclusion. Upon narrowing the scope to isolate StUDs, 179 sources were included for full-text review, with 90 included for extraction. The most common outcome measure assessed was craving, with cognition, affective symptoms, sleep, and use patterns other frequently assessed measures. Overall, the results appear promising, with non-invasive neurostimulation variably improving cravings, cognition and affective outcomes in patients with StUDs. However, this review identified some limitations that require further research attention, including small sample sizes, short follow-up periods, protocol heterogeneity, and ill-representative samples.

## Full-text entities

- **Genes:** EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}
- **Diseases:** drug (MESH:D000081015), Depression (MESH:D003866), cardiovascular, cerebrovascular, respiratory, infectious and kidney disease (MESH:D007674), scalp tingling (MESH:D004476), Impulsivity (MESH:D007174), tingling (MESH:D010292), baffective symptoms (MESH:D012816), depressive and withdrawal symptoms (MESH:D013375), neurological event (MESH:D002318), amphetamine (MESH:D019969), psychosis (MESH:D011618), ADHD (MESH:D001289), neuropsychiatric (MESH:C000631768), cocaine dependency (MESH:D019970), affective disorders (MESH:D019964), suicidal ideation (MESH:D001072), heroin and alcohol addictions (MESH:D006556), Sleepiness (MESH:D000077260), opioid addiction (MESH:D009293), anxiety symptoms (MESH:D001008), headache (MESH:D006261), Craving (MESH:C564883), anhedonia (MESH:D059445), Addictive disorders (MESH:D000437), CUD (MESH:C536778), Mental Disorders (MESH:D001523), SUD (MESH:D019966), Anxiety (MESH:D001007)
- **Chemicals:** glutamine (MESH:D005973), H (MESH:D006859), alcohol (MESH:D000438), Cocaine Use Disorder (-), methamphetamine (MESH:D008694), crack-cocaine (MESH:D016578), NAA (MESH:C000179), cocaine (MESH:D003042), nicotine (MESH:D009538), Zno (MESH:D015034), TBS (MESH:D013725), GABA (MESH:D005680), glutamate (MESH:D018698), THC (MESH:D013759)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913103/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12913103/full.md

## References

105 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913103/full.md

---
Source: https://tomesphere.com/paper/PMC12913103